Regenxbio, Duchenne muscular dystrophy and gene therapy
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne, commemorated its 30th ...
Columnist Shalom Lim tells an international conference about his experiences with inclusion during his education in Singapore ...
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular ...
Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...
a potential best-in-class gene therapy for Duchenne muscular dystrophy, has advanced to pivotal stage and dosed its first patient. The company also announced new, positive efficacy and safety ...
Elevidys, a gene therapy from Sarepta Therapeutics (SRPT.O), opens new tab approved in the United States last year for ...
It’s easy for those who play or watch the best movies based on video games to want to be immersed in that fictional world.
Analyst Gena Wang from Barclays maintained a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $50.00.Don't Miss ...
Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback